Protesting Icagen VCs want to know what Pfizer knows
This article was originally published in Scrip
Executive Summary
Shareholders protesting about the price agreed by Icagen's directors for the company's sale to Pfizer believe the latter may be sitting on Phase I data which give it a better idea of Icagen's value than other stockholders are able to assess.